Rung 5 · Established
Gene-matched drugs for metastatic prostate cancer
Two 2026 approvals reward genetic testing of the tumor.
TreatmentWith your doctor
What studies found
Capivasertib with abiraterone was approved June 12, 2026 for PTEN-deficient metastatic cancer (CAPItello-281, 1,012 patients). Talazoparib with enzalutamide was approved October 26, 2026 for HRR-mutated metastatic cancer that still responds to hormone therapy (TALAPRO-3, 599 patients).
The catch
Each requires a companion test showing the specific gene change.
What to do
Ask for tumor and inherited genetic testing if your cancer has spread.
Sources
Rung 5 of 5, Established: Large randomized trials or overwhelming, consistent human evidence; reflected in major guidelines. How we score
To take it to your doctor, print this page.
Step by step
For the whole picture, from prevention and screening to treatment and life after, see the prostate cancer page.
Related
- Active surveillance for low-risk prostate cancerRung 5 · EstablishedWith your doctorRung 5 · EstablishedTreatmentWith your doctor
- PSMA radioligand therapy (Pluvicto)Rung 5 · EstablishedWith your doctorRung 5 · EstablishedTreatmentWith your doctor
- Exercise for prostate health and surveillanceRung 3 · ModerateYou can do thisRung 3 · ModerateTreatmentYou can do this
- High omega-3, low omega-6 diet with fish oilRung 2 · LimitedWith your doctorRung 2 · LimitedTreatmentWith your doctor
- Standard treatment from your oncology teamRung 5 · EstablishedWith your doctorRung 5 · EstablishedTreatmentWith your doctor